152 related articles for article (PubMed ID: 6703716)
1. [Basic rules and problems of phase study of new anticancer agents].
Saito T
Gan To Kagaku Ryoho; 1984 Mar; 11(3):377-82. PubMed ID: 6703716
[TBL] [Abstract][Full Text] [Related]
2. [Preclinical data as basis for the design of clinical studies].
Fichtner I
Onkologie; 2008; 31 Suppl 2():34-8. PubMed ID: 18487867
[TBL] [Abstract][Full Text] [Related]
3. Anticancer Drug Development: The Way Forward.
Connors T
Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
[TBL] [Abstract][Full Text] [Related]
4. [A tentative of guideline for phase III study and its problems in clinical aspect].
Nakao I
Gan To Kagaku Ryoho; 1984 Mar; 11(3):395-403. PubMed ID: 6703719
[TBL] [Abstract][Full Text] [Related]
5. Improving the evaluation of new cancer treatments: challenges and opportunities.
Rothenberg ML; Carbone DP; Johnson DH
Nat Rev Cancer; 2003 Apr; 3(4):303-9. PubMed ID: 12671669
[TBL] [Abstract][Full Text] [Related]
6. [Phase I clinical trial design of anticancer agents--a Fibonacci and a modified Fibonacci sequence].
Kusaba H; Tamura T
Gan To Kagaku Ryoho; 2000 May; 27(5):775-8. PubMed ID: 10832451
[TBL] [Abstract][Full Text] [Related]
7. [Introduction of anticancer agents to phase I clinical trials].
Shimoyama M
Gan To Kagaku Ryoho; 1997 Jan; 24(2):246-55. PubMed ID: 9030238
[TBL] [Abstract][Full Text] [Related]
8. Strategy for the development of novel anticancer drugs.
Saijo N; Tamura T; Nishio K
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S97-101. PubMed ID: 12856152
[TBL] [Abstract][Full Text] [Related]
9. [Current problems in development of new anticancer agents for new molecular targets].
Nishii K
Gan To Kagaku Ryoho; 1996 Jan; 23(2):211-8. PubMed ID: 8611049
[TBL] [Abstract][Full Text] [Related]
10. [Current status and issues in clinical trials of anticancer agents].
Kojima H
Gan To Kagaku Ryoho; 1994 Oct; 21 Suppl 3():295-301. PubMed ID: 7986107
[TBL] [Abstract][Full Text] [Related]
11. The last patient in a drug trial.
Hastings Cent Rep; 1981 Dec; 11(6):21-3. PubMed ID: 7333839
[No Abstract] [Full Text] [Related]
12. Good clinical practice in clinical drug trials--what you need to know.
Soyebi K; Abosede ; Coker HA; Osuntoki ; Oyibos W; Keri H; Ogunsola S
Nig Q J Hosp Med; 2008; 18(2):104-12. PubMed ID: 19068563
[No Abstract] [Full Text] [Related]
13. Guidelines for the clinical evaluation of antianxiety drugs. HEW (FDA) 77-3043, September 1977.
Methods Find Exp Clin Pharmacol; 1979 Dec; 1(5):297-312. PubMed ID: 45205
[No Abstract] [Full Text] [Related]
14. [Guideline for phase I study on new anticancer agents].
Shimoyama M
Gan To Kagaku Ryoho; 2001 Feb; 28(2):261-70. PubMed ID: 11242659
[TBL] [Abstract][Full Text] [Related]
15. Clinical development plan: N-Acetyl-l-cysteine.
Kelloff GJ; Crowell JA; Boone CW; Steele VE; Lubet RA; Greenwald P; Alberts DS; Covey JM; Doody LA; Knapp GG
J Cell Biochem Suppl; 1994; 20():63-73. PubMed ID: 7616754
[No Abstract] [Full Text] [Related]
16. Clinical trials: a basic bibliography (#44).
Matzke GR
Hosp Pharm; 1988 Jun; 23(6):600. PubMed ID: 10302529
[No Abstract] [Full Text] [Related]
17. Critique of the Guidelines for Clinical Evaluation of Antianxiety Drugs (HEW-FDA-77-3043).
Cohn JB; Gottschalk LA
Methods Find Exp Clin Pharmacol; 1979 Dec; 1(5):313-5. PubMed ID: 45206
[No Abstract] [Full Text] [Related]
18. Alternative strategies in drug development: clinical pharmacological aspects.
Kuhlmann J
Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
[TBL] [Abstract][Full Text] [Related]
19. Drug research: from the idea to the product.
Kuhlmann J
Int J Clin Pharmacol Ther; 1997 Dec; 35(12):541-52. PubMed ID: 9455711
[TBL] [Abstract][Full Text] [Related]
20. Testing of intraocular drugs for clinical use.
Kozak I; Cheng L; Silva GA; Freeman WR
Invest Ophthalmol Vis Sci; 2007 Nov; 48(11):4861-3. PubMed ID: 17962431
[No Abstract] [Full Text] [Related]
[Next] [New Search]
